A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT06254599 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

255

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: SY-3505 Capsules
DRUG: Crizotinib Capsules

Sponsor

Shouyao Holdings (Beijing) Co. LTD